Clozapine-induced weight gain: prevalence and clinical relevance.
about
Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophreniaA current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data.Olanzapine optimal dose: results of an open-label multicenter study in schizophrenic patients. Olanzapine Late-Phase II Study Group.Genetics of antipsychotic treatment emergent weight gain in schizophrenia.Body weight gain induced by antipsychotic drugs: mechanisms and management.Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities.Euglycemic clamp study in clozapine-induced diabetic ketoacidosis.Diabetes mellitus and other metabolic disturbances induced by atypical antipsychotic agents.Eating and weight related cognitions in people with Schizophrenia : a case control studyBehavioural management of antipsychotic-induced weight gain: a review.Hyperglycemia with antipsychotic treatment.Illuminating the molecular basis for some antipsychotic drug-induced metabolic burden.Interventions for Weight Gain in Adults Treated With Novel Antipsychotics.Atypical Antipsychotic Use in the Treatment of Psychosis in Primary CareA Perspective on the Primary Care of Patients With Behavior, Mood, and Thought Disturbances: Clinical Applications of Olanzapine.Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatmentAre cardiometabolic and endocrine abnormalities linked to sleep difficulties in schizophrenia? A hypothesis driven reviewA Longitudinal Study of Relation between Side-effects and Clinical Improvement in Schizophrenia: Is There a Neuro-metabolic Threshold for Second Generation Antipsychotics?Associations among obesity, acute weight gain, and response to treatment with olanzapine in adolescent schizophrenia.Analysis of copy number variations at 15 schizophrenia-associated loci.Mechanisms and genetics of antipsychotic-associated weight gain.Treatment of clozapine-associated weight gain: a systematic review.Intrinsic and Antipsychotic Drug-Induced Metabolic Dysfunction in Schizophrenia.Atypical antipsychotics and effects on feeding: from mice to men.Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients.Clozapine in the treatment of refractory schizophrenia: Canadian policies and clinical guidelines.Clozapine therapy in patients with neurologic illness.Peroxisome proliferator-activated receptor gamma (PPARG) Pro12Ala: lack of association with weight gain in psychiatric inpatients treated with olanzapine or clozapine.Peripheral injection of risperidone, an atypical antipsychotic, alters the bodyweight gain of rats.Obesity in schizophrenic outpatients receiving antipsychotics in Taiwan.Clozapine-induced weight gain associated with the 5HT2C receptor -759C/T polymorphism.Association study of brain-derived neurotrophic factor gene polymorphisms and body weight change in schizophrenic patients under long-term atypical antipsychotic treatment.Weight gain in children and adolescents during 45 weeks treatment with clozapine, olanzapine and risperidone.Resistance to excessive bodyweight gain in risperidone-injected rats.A prospective study of serum ghrelin levels in patients treated with clozapine.Competitive displacement of clozapine from plasma proteins in normolipidemic and hyperlipidemic plasma samples: clinical implications.DRD4 48 bp VNTR but not 5-HT 2C Cys23Ser receptor polymorphism is related to antipsychotic-induced weight gain.Antipsychotic drug-induced obesity in rats: correlation between leptin, insulin and body weight during sulpiride treatment.Weight changes during clozapine treatment.Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents.
P2860
Q24798487-C3D3C01D-0793-4A38-A536-7C3CA36BB7E4Q30667146-AF916DC6-E4F6-494A-87B4-CA08B83737E6Q31440445-6806146F-5CD4-4062-9BF8-9B6DE2D7A914Q33257886-AACE4BE0-43A2-42A0-97F6-2A89EBE1BA0EQ33708467-CD7F406F-0F10-45B7-8881-6E00A2B03B03Q34230366-129A8AC1-ED9D-40C8-A658-BB286C83F220Q34449430-F8E85D23-B184-46D7-A1AF-564622AE563BQ35087431-05ACBB9F-EBE3-4DAC-B543-5CBC252BB0C4Q35126654-F6B5B60F-B6B1-4664-A005-11B3AA4AFCFDQ35212362-A402016A-B835-4099-8E8F-E5C09A5D1A19Q35649416-A048712A-487A-42F2-9FFF-51141FD44A8AQ35652340-384E61EA-236A-4497-B744-DF1556C9A56EQ35664958-1C1EE950-7518-4D2F-9695-DA7D8A9C7BCFQ35665593-15035C76-8010-48A7-AF5F-3F396A67A9BBQ35666903-ED9F5844-1AD7-4D1E-B5CD-5E424939DB74Q35968139-63385F93-9756-4DC0-9456-A5E9948455BDQ36600817-CE58F46E-A780-418C-8B2E-678428060964Q36832340-358CCC40-3660-429A-B43B-4FC0598C9371Q37244634-21123104-2647-4B0E-BECA-32A2A552104DQ37541157-CF292017-727F-403A-8D4F-CFACC21F2AADQ37883895-E068E3EF-1AD8-4423-A225-63BAB40736CFQ38334922-FB9B6E31-4A97-4576-A024-E86596B5F78DQ38626655-28D1B455-289E-4848-A6FD-0ED37E9BF416Q38850666-60756EB7-BE11-4D0F-B22E-2DA1F7572D83Q40255006-C18B2C96-5BE8-4890-AB88-2FB8F8FB2321Q41108984-D0B53153-CF8B-4F48-A316-F8904E2692EAQ41122440-10F00293-5FAD-4B14-A7ED-BD0CD4F8DBFDQ44157498-A1324200-7B4F-4237-BA71-14DC49949298Q44169297-9A465904-8A60-476B-A6A4-471C659420FEQ45009922-999D69FE-5D9E-4DE9-842A-1CE4BDC47412Q45213994-45C5B55E-9028-4CDA-80F1-7A6B29EC1921Q46117105-4005EDA8-0545-45CF-A3E9-5EA5605FE6C7Q46380164-F3554581-6A8C-4796-8CAF-0291D87CE6CAQ46422509-79F22E86-B34F-437F-8A85-55BA4AA98C0EQ46549774-978E28FB-4718-4147-A7B8-3F2E777BAE92Q46644149-EC82D33E-B55F-42CB-9E52-9CC7791C9AB0Q46708448-3EB41CB2-2097-48D4-A0B0-AF2B93557245Q47247035-330080B5-FD87-4745-8D28-A58FDAAC95EEQ47277973-574FF817-9DA4-440B-B618-16585F428AEDQ47313667-B283CEDA-385F-46DE-852A-2B38077E0EBD
P2860
Clozapine-induced weight gain: prevalence and clinical relevance.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh-hant
name
Clozapine-induced weight gain: prevalence and clinical relevance.
@en
Clozapine-induced weight gain: prevalence and clinical relevance.
@nl
type
label
Clozapine-induced weight gain: prevalence and clinical relevance.
@en
Clozapine-induced weight gain: prevalence and clinical relevance.
@nl
prefLabel
Clozapine-induced weight gain: prevalence and clinical relevance.
@en
Clozapine-induced weight gain: prevalence and clinical relevance.
@nl
P2093
P356
P1476
Clozapine-induced weight gain: prevalence and clinical relevance.
@en
P2093
P356
10.1176/AJP.149.1.68
P407
P577
1992-01-01T00:00:00Z